Nuvectis Pharma (NVCT) Expected to Release Quarterly Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) is expected to release its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Nuvectis Pharma to post earnings of ($0.25) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 9:30 AM ET.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. On average, analysts expect Nuvectis Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nuvectis Pharma Trading Down 2.5%

NASDAQ:NVCT traded down $0.49 during mid-day trading on Tuesday, reaching $19.05. 17,872 shares of the stock were exchanged, compared to its average volume of 158,706. The business has a fifty day moving average price of $15.56 and a 200 day moving average price of $11.17. The firm has a market capitalization of $505.50 million, a PE ratio of -14.65 and a beta of -0.24. Nuvectis Pharma has a 1-year low of $5.55 and a 1-year high of $29.27.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on NVCT shares. UBS Group set a $33.00 price objective on shares of Nuvectis Pharma in a research note on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvectis Pharma in a research report on Friday, June 5th. Wall Street Zen upgraded Nuvectis Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. HC Wainwright raised their price objective on Nuvectis Pharma from $13.00 to $39.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Finally, Roth Capital boosted their target price on Nuvectis Pharma from $20.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $35.00.

Insider Activity at Nuvectis Pharma

In other news, major shareholder Marlio Charles Mosseri acquired 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was purchased at an average price of $18.32 per share, with a total value of $916,000.00. Following the purchase, the insider owned 3,186,576 shares of the company’s stock, valued at approximately $58,378,072.32. This trade represents a 1.59% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Ron Bentsur acquired 12,500 shares of the stock in a transaction on Tuesday, June 30th. The shares were purchased at an average price of $20.00 per share, for a total transaction of $250,000.00. Following the completion of the transaction, the chief executive officer owned 3,688,424 shares in the company, valued at approximately $73,768,480. This represents a 0.34% increase in their position. The SEC filing for this purchase provides additional information. 28.55% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. acquired a new position in Nuvectis Pharma during the first quarter valued at $446,000. Jane Street Group LLC acquired a new stake in Nuvectis Pharma during the 1st quarter worth about $413,000. Geode Capital Management LLC boosted its position in Nuvectis Pharma by 110.8% during the 2nd quarter. Geode Capital Management LLC now owns 285,332 shares of the company’s stock worth $2,132,000 after acquiring an additional 149,999 shares during the period. JPMorgan Chase & Co. grew its stake in Nuvectis Pharma by 3,398.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock valued at $47,000 after acquiring an additional 6,084 shares in the last quarter. Finally, New York State Common Retirement Fund purchased a new position in Nuvectis Pharma during the 2nd quarter valued at about $97,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.